These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Dees C; Tomcik M; Palumbo-Zerr K; Distler A; Beyer C; Lang V; Horn A; Zerr P; Zwerina J; Gelse K; Distler O; Schett G; Distler JH Arthritis Rheum; 2012 Sep; 64(9):3006-15. PubMed ID: 22549363 [TBL] [Abstract][Full Text] [Related]
9. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. Pannu J; Gore-Hyer E; Yamanaka M; Smith EA; Rubinchik S; Dong JY; Jablonska S; Blaszczyk M; Trojanowska M Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427 [TBL] [Abstract][Full Text] [Related]
10. Activation of the activin A-ALK-Smad pathway in systemic sclerosis. Takagi K; Kawaguchi Y; Kawamoto M; Ota Y; Tochimoto A; Gono T; Katsumata Y; Takagi M; Hara M; Yamanaka H J Autoimmun; 2011 May; 36(3-4):181-8. PubMed ID: 21377836 [TBL] [Abstract][Full Text] [Related]
11. Scar wars: is TGFbeta the phantom menace in scleroderma? Leask A Arthritis Res Ther; 2006; 8(4):213. PubMed ID: 16774692 [TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Verrecchia F; Mauviel A; Farge D Autoimmun Rev; 2006 Oct; 5(8):563-9. PubMed ID: 17027893 [TBL] [Abstract][Full Text] [Related]
13. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Ihn H; Yamane K; Kubo M; Tamaki K Arthritis Rheum; 2001 Feb; 44(2):474-80. PubMed ID: 11229480 [TBL] [Abstract][Full Text] [Related]
14. Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β-Dependent Fibroblast Activation. Fang F; Marangoni RG; Zhou X; Yang Y; Ye B; Shangguang A; Qin W; Wang W; Bhattacharyya S; Wei J; Tourtellotte WG; Varga J Arthritis Rheumatol; 2016 Aug; 68(8):1989-2002. PubMed ID: 26946325 [TBL] [Abstract][Full Text] [Related]
16. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Leask A Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619 [TBL] [Abstract][Full Text] [Related]
18. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795 [TBL] [Abstract][Full Text] [Related]
19. Skin involvement in scleroderma--where histological and clinical scores meet. Verrecchia F; Laboureau J; Verola O; Roos N; Porcher R; Bruneval P; Ertault M; Tiev K; Michel L; Mauviel A; Farge D Rheumatology (Oxford); 2007 May; 46(5):833-41. PubMed ID: 17255134 [TBL] [Abstract][Full Text] [Related]
20. Fibroblast abnormalities in the pathogenesis of systemic sclerosis. Usategui A; del Rey MJ; Pablos JL Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]